KEY TAKEAWAYS
- The study aimed to examine JAK2 levels’ association with CHR and early molecular response post-3-month imatinib treatment in chronic phase CML.
- The results revealed that JAK2 levels could be a potential indicator for assessing imatinib treatment response in CML, given its involvement in the disease’s pathophysiology.
Chronic myeloid leukemia (CML), also known as chronic granulocytic leukemia, is characterized by the presence of the Philadelphia (Ph+) chromosome, indicating a myeloproliferative neoplasm. Imatinib, a first-line tyrosine kinase inhibitor, remains fundamental in treatment protocols. However, treatment resistance has been observed, partly attributed to the role of additional genes like Janus kinase 2 (JAK2).
Indra Wijaya and the team aimed to assess the correlation between JAK2 levels and complete hematological response (CHR) and early molecular response (EMR) post-3-month imatinib therapy in patients with chronic phase CML.
Patients diagnosed with Ph+ CML in the chronic phase (n = 40; mean age, 40 ± 11 years) were enrolled to undergo assessments, which included clinical examination and blood tests. These evaluations, including complete blood counts and JAK2 levels, were conducted at baseline and after 3 months of treatment with imatinib (at a daily oral dose of 400 mg). Participants were categorized into 2 groups based on the presence or absence of CHR and EMR.
The results revealed that in the group exhibiting CHR and EMR, levels of JAK2 gene, phosphorylated, and total JAK2 proteins were notably lower at baseline. Furthermore, a negative correlation was observed between baseline JAK2 levels, including JAK2 gene expression, phosphorylated and total JAK2 proteins, and CHR and EMR.
The study concluded that JAK2 levels could serve as an indicator for assessing treatment response to imatinib in individuals with CML, given their involvement in the disease’s pathophysiology.
No funding-related information was available.
Source: https://pubmed.ncbi.nlm.nih.gov/38716474/
Wijaya I, Bashari MH, Reniarti L, et al. (2024). “JAK2 as Predictor of Therapeutic Response in Patients with Chronic Myeloid Leukemia Treated with Imatinib.” Dis Markers. 2024 Apr 12;2024:2906566. doi: 10.1155/2024/2906566. PMID: 38716474; PMCID: PMC11074917.
